GlassScriptPhysician profile
Muhammad I Choudhry
NPI 1396003588
$3,180.54
in general payments reported to CMS, 2019-2025
33 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 90% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $412 · 2022: $485 · 2023: $367 · 2024: $913 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,271 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,271.07 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $841.39 | 2021-2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $300.83 | 2022-2025 | Mounjaro, Jardiance |
| Phathom Pharmaceuticals, INC. | $183.52 | 2024-2025 | Voquezna |
| Abbott Laboratories | $180.51 | 2021 | |
| Novo Nordisk INC | $162.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Madrigal Pharmaceuticals | $149.23 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.44 | 2021-2024 | Jardiance |
| Abbvie INC. | $131.40 | 2021-2025 | |
| Ardelyx, INC. | $122.38 | 2025 | Ibsrela |
| Sumitomo Pharma America, INC. | $104.72 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $93.11 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.99 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $87.04 | 2024-2025 | Zenpep |
| Neurelis, INC. | $68.10 | 2023 | Valtoco |
| Nevro Corp. | $66.21 | 2022-2023 | Senza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.08 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $44.87 | 2023-2024 | Rexulti, Abilify Asimtufii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.42 | 2023-2024 | Xifaxan |
| Boston Scientific Corporation | $34.27 | 2025 | Wavewriter Alpha Prime 16 |
| Alkermes, INC. | $33.03 | 2021-2025 | Vivitrol |
| Abiomed | $30.00 | 2025 | |
| Ucb, INC. | $29.82 | 2023 | Briviact |
| Scilex Pharmaceuticals INC. | $21.85 | 2022 | |
| Mylan Specialty L.P. | $20.74 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.39 | 2024 | Crysvita |
| Avanir Pharmaceuticals, INC. | $18.75 | 2022 | |
| Medtronic, INC. | $17.31 | 2025 | Inceptiv |
| Glaxosmithkline, LLC. | $17.25 | 2023 | Bexsero, Shingrix |
| Mannkind Corporation | $15.68 | 2025 | |
| Acadia Pharmaceuticals INC | $15.59 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.35 | 2023 | Rexulti |
| Lundbeck LLC | $15.10 | 2023 | Rexulti |
| Gilead Sciences, INC. | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Choudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.